Related references
Note: Only part of the references are listed.Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases
Manon Belhassen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database
Peter Hur et al.
DRUGS-REAL WORLD OUTCOMES (2021)
Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis
Julie Vanderpoel et al.
CLINICAL THERAPEUTICS (2019)
Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK
Miriam Tarallo et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients
Ahva Shahabi et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Web Site and R Package for Computing E-values
Maya B. Mathur et al.
EPIDEMIOLOGY (2018)
The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany
Kathrin Ziegelbauer et al.
RHEUMATOLOGY (2018)
Sensitivity Analysis in Observational Research: Introducing the E-Value
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2017)
Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
Luca Degli Esposti et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2017)
Economic Burden of Psoriasis and Potential Cost Offsets with Biologic Treatment: A Swedish Register Analysis
Axel Svedbom et al.
ACTA DERMATO-VENEREOLOGICA (2016)
Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
Grant W. Cannon et al.
ADVANCES IN THERAPY (2016)
Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
Johan Dalen et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system
Nazia Rashid et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Sick leave patterns in common musculoskeletal disorders - a study of doctor prescribed sick leave
Jenny Hubertsson et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting
Brian Meissner et al.
JOURNAL OF MEDICAL ECONOMICS (2014)
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
L. Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
BIOLOGIC THERAPY PATTERNS AND ASSOCIATED COSTS IN RHEUMATOID ARTHRITIS PATIENTS WHO INITIATED A TUMOR NECROSIS FACTOR ANTAGONIST OVER TWO YEARS
H. Wang et al.
VALUE IN HEALTH (2012)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
External review and validation of the Swedish national inpatient register
Jonas F. Ludvigsson et al.
BMC PUBLIC HEALTH (2011)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis
Boxiong Tang et al.
CLINICAL THERAPEUTICS (2008)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
The new Swedish Prescribed Drug Register -: Opportunities for pharmacoepidemiological research and experience from the first six months
Bjorn Wettermark et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference
Daniel E. Ho et al.
POLITICAL ANALYSIS (2007)
Rheumatoid arthritis:: what does it cost and what factors are driving those costs?: Results of a survey in a community-derived population in Malmo, Sweden
L. T. H. Jacobsson et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2007)
Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income:: experience from the FIN-RACo trial
K. Puolakka et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Share Paper
